Cancer is a severe diseases causing millions of death worldwide every year. Cancer starts from a single cell and genetically transforms a normal cell in to tumour cell and is gradually spread to other cells. With the dramatic increase in the number of people affected by cancer, many pharmaceutical players started to invest on monoclonal antibodies. While the drugs are used for the treatment of cancer, drugs like chemotherapy agents have adverse side effects as they affect the normal cells as well along with cancerous cells. This prompted the increased usage of Monoclonal Antibodies for the treatment of cancer.
Latin America Monoclonal Antibodies Market which is a USD 4.46 billion market in 2018 is expected to reach USD 7.01 billion by 2023 with a significant CAGR of 9.5%.
Recent years have seen the emergence of monoclonal antibodies market, offering less toxic and highly efficient therapeutics alternatives. The antibody agents are used to cure a wide array of diseases, especially cancer, autoimmune and inflammatory diseases. They are mono-specific antibodies having identical immune cells that are clone to the single parent cells and are directed to a specific target cell. This customizable feature of the antibodies due to its specific nature can play a critical role in eliminating the cancer cell while sparing the healthy cells. Monoclonal antibodies are more effective in treating cancer than their counter parts like drugs or chemotherapy owing to their adverse side effects.
Increased prevalence of cancer disease is the primary driver for the market. It has led many pharmaceutical companies to invest heavily in monoclonal antibodies due to its customizable nature of attacking only the cancer cell. The other drivers for the market include increasing investments in R&D of genomic studies, advancements in target gene selection and genetic sequencing and specificity of antibodies to target only the cancer cells. There are also hurdles prevailing for the monoclonal antibodies market like high costs of development, strict guidelines by the governments, longer periods required for clinical trials and research & development.
The segmentation of the Latin America on the basis of application is categorised as Leukaemia, Colorectal, Liver, Brain, Breast, Blood, Hodgkins & Non-Hodgkins lymphoma and others. The segmentation based on type is divided as murine antibodies, fully humanised antibodies and chimeric & humanised antibodies. By Conjugated Cancer Therapies it is segmented as Radioimmunotherapy, Immunoliposome, ADEPT, Immunocytokines and others. Based on the geography of Latin America it is analysed in Brazil, Argentina, Mexico and others.
The key players of the market are Amgen, Eli Lilly, Bristol Myers Squibb, Roche, Immunogen, Genmab, Novartis, Glaxosmithkline, Spectrum Pharaceuticals and Seattle Genetics
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Application
5.1.1 Liver
5.1.2 Breast
5.1.3 Brain
5.1.4 Blood
5.1.5 Hodgkins and Non-Hodgkins lymphoma
5.1.6 Colorectal
5.1.7 Leukaemia
5.1.8 Others
5.2 By Type
5.2.1 Murine Antibodies
5.2.2 Chimeric and Humanised Antibodies
5.2.3 Fully Humanized Antibodies
5.3 Conjugate Cancer Therapies
5.3.1 Immunoliposome
5.3.2 Radioimmunotherapy
5.3.3 ADEPT
5.3.4 Immunocytokines
5.3.5 Others
6.1 Introduction
6.2 Brazil
6.3 Mexico
6.4 Rest of Latin America
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Roche
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Amgen
8.3 Genmab
8.4 Glaxosmithkline
8.5 Bristol Meyer Squibb
8.6 Eli Lilly
8.7 Immunogen
8.8 Novartis
8.9 Seattle Genetics
8.10 Spectrum Pharmaceuticals
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
